| Medical and Health Sciences | 2021-2025 | 240 | CN 24 | 99.95 |
| Biological Sciences | 2021-2025 | 518 | CN 182 | 99.44 |
| Oncology | Lifetime | 417 | CN 10 | 99.28 |
| Pulmonary and Respiratory Medicine | Lifetime | 742 | CN 14 | 98.89 |
| Cancer Research | Lifetime | 326 | CN 24 | 98.06 |
| Aquatic Science and Fisheries | Lifetime | 400 | CN 54 | 95.09 |
| Oncology | 2021-2025 | 56 | CN 6 | 99.71 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 84 | CN 11 | 99.54 |
| Surgery | 2021-2025 | 138 | CN 9 | 99.18 |
| Cancer Research | 2021-2025 | 48 | CN 22 | 98.19 |
| Molecular Biology | 2021-2025 | 579 | CN 239 | 96.88 |
| Immunology | 2021-2025 | 267 | CN 63 | 93.54 |
| Epidemiology | 2021-2025 | 951 | CN 99 | 90.08 |
| Aquatic Science and Fisheries | 2021-2025 | 183 | CN 51 | 88.04 |
| Cancer-related molecular mechanisms research | Lifetime | 259 | CN 118 | 98.98 |
| Ferroptosis and cancer prognosis | Lifetime | 81 | CN 27 | 98.61 |
| MicroRNA in disease regulation | Lifetime | 317 | CN 112 | 98.83 |
| Esophageal Cancer Research and Treatment | Lifetime | 138 | CN 3 | 99.09 |
| Lung Cancer Treatments and Mutations | Lifetime | 328 | CN 7 | 99.17 |
| Multiple and Secondary Primary Cancers | Lifetime | 96 | CN 3 | 98.70 |
| RNA modifications and cancer | Lifetime | 621 | CN 70 | 98.77 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 425 | CN 18 | 99.02 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 465 | CN 16 | 98.73 |
| Global Cancer Incidence and Screening | Lifetime | 325 | CN 6 | 98.32 |
| Aquaculture Nutrition and Growth | Lifetime | 665 | CN 72 | 97.89 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 842 | CN 166 | 89.28 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 106 | CN 16 | 99.57 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 11 | CN 3 | 98.12 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 59 | CN 8 | 98.36 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 99 | CN 19 | 98.74 |
| Global Cancer Incidence and Screening | 2021-2025 | 61 | CN 8 | 98.28 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 138 | CN 20 | 99.09 |
| RNA modifications and cancer | 2021-2025 | 217 | CN 143 | 97.90 |
| Cancer Genomics and Diagnostics | 2021-2025 | 345 | CN 25 | 97.57 |
| Ferroptosis and cancer prognosis | 2021-2025 | 193 | CN 153 | 96.86 |
| Cancer-related molecular mechanisms research | 2021-2025 | 401 | CN 308 | 96.75 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 368 | CN 63 | 96.92 |
| Colorectal Cancer Screening and Detection | 2021-2025 | 242 | CN 25 | 95.84 |
| MicroRNA in disease regulation | 2021-2025 | 447 | CN 279 | 95.04 |
| Lung Cancer Research Studies | 2021-2025 | 376 | CN 76 | 95.54 |
| Immune cells in cancer | 2021-2025 | 524 | CN 292 | 91.84 |
| Esophageal and GI Pathology | 2021-2025 | 721 | CN 50 | 91.23 |
| Aquaculture Nutrition and Growth | 2021-2025 | 935 | CN 433 | 90.32 |
| Cancer Risks and Factors | 2021-2025 | 328 | CN 25 | 87.08 |
| Marine Bivalve and Aquaculture Studies | 2021-2025 | 478 | CN 154 | 88.40 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 302 | CN 118 | 75.62 |
| Cancer-related Molecular Pathways | 2021-2025 | 891 | CN 193 | 72.67 |
| Reproductive biology and impacts on aquatic species | 2021-2025 | 778 | CN 263 | 69.96 |
| Crustacean biology and ecology | 2021-2025 | 563 | CN 148 | 64.86 |
| TGF-β signaling in diseases | 2021-2025 | 275 | CN 84 | 53.08 |
